Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 92 of 179 for:    colon cancer | ( Map: New Jersey, United States )

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00252564
Recruitment Status : Completed
First Posted : November 11, 2005
Results First Posted : March 14, 2011
Last Update Posted : February 15, 2019
Sponsor:
Collaborators:
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Prologue Research International
Information provided by (Responsible Party):
US Oncology Research

Brief Summary:
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Bevacizumab Drug: Oxaliplatin Drug: Leucovorin Drug: Fluorouracil Drug: Cetuximab Phase 3

Detailed Description:

This is a Phase III, open label, nonblinded study. A total of 240 eligible patients will be randomized on a 1:1 basis to either treatment Arm.

In this trial, we will compare the efficacy, safety, and tolerability of this novel combination of biweekly infusional 5-FU/leucovorin plus cetuximab and bevacizumab (FOLF-CB) to the current standard of care, biweekly infusional 5-FU/leucovorin plus oxaliplatin and bevacizumab (Bev-FOLFOX). For practical purposes, this study will be a head to head comparison of oxaliplatin versus cetuximab, since the other components of both regimens will be the same.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 247 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer
Study Start Date : September 2005
Actual Primary Completion Date : June 2007
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Bev-FOLFOX

(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.

Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU

Dosing on Days 1 and 15 of each 28-day cycle

Drug: Bevacizumab
5 mg/kg over 30 minutes on Days 1 and 15
Other Name: Avastin

Drug: Oxaliplatin
85 mg/m2 on Days 1 and 15
Other Name: Eloxatin

Drug: Leucovorin
400 mg/m2 on Days 1 and 15

Drug: Fluorouracil
400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
Other Name: 5FU

Experimental: FOLF-CB

(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.

Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU

Drug: Bevacizumab
5 mg/kg over 30 minutes on Days 1 and 15
Other Name: Avastin

Drug: Leucovorin
400 mg/m2 on Days 1 and 15

Drug: Fluorouracil
400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
Other Name: 5FU

Drug: Cetuximab
400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
Other Name: Erbitux




Primary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: 12 months ]

    From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).

    Kaplan-Meier median PFS time and PFS rate (at 12 months)


  2. Progression-free Survival (PFS) Rate at 1 Year. [ Time Frame: 12 months ]
    From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: up to 4 years ]

    From randomization to death (event); or last follow-up date if alive (censoring).

    Kaplan-Meier OS median time.


  2. Objective Response Rate [ Time Frame: 12 months ]
    Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all "per-protocol population" patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • Histologically or cytologically confirmed colorectal cancer with metastatic disease
  • Measurable disease
  • Previously irradiated lesions will be considered evaluable, if they progressed since radiation
  • Has disease other than limited to surgically resectable liver-only or lung-only metastatic disease
  • Not received prior chemo and/or biotherapy for metastatic disease
  • Not received oxaliplatin, bevacizumab, or cetuximab in the adjuvant setting
  • May have received 5-FU, leucovorin, and/or irinotecan in the adjuvant setting, however must have remained free of disease recurrence (including free of abnormal CEA level) for 1- year or more
  • Is >18 years of age
  • ECOG performance status 0 or 1
  • Normal organ & marrow function
  • Use of an acceptable method of birth control
  • Not pregnant or breast feeding
  • Paraffin tissue block(s) or 12 (minimum) unstained slides available, for assessment of potential predictive markers related to the EGFR, VEGF, DNA repair, and fluoropyrimidine catabolism pathways. If no block is available, slides (typically 7 to 10 um sections, air dried on uncharged slides) may be sent
  • Signed a Patient Informed Consent Form
  • Signed a Patient Authorization Form (HIPAA) Form

EXCLUSION CRITERIA:

  • Had prior chemotherapy for metastatic colorectal cancer
  • Received any prior treatment with oxaliplatin, bevacizumab, or cetuximab in the adjuvant treatment of their colorectal cancer
  • Currently receiving any other investigational anticancer agents or has participated in an experimental drug study within the past 4 weeks
  • History of primary CNS tumors, seizures not well-controlled with standard medical therapy, or stroke
  • Sustained hypertension, as characterized by persistent blood pressures greater than 150/100 despite medical management
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure or has had angioplasty or placement of coronary stents within the past 6 months
  • Clinically significant peripheral vascular disease
  • History of serious allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, cetuximab, oxaliplatin, fluorouracil, leucovorin, or other agents used in the study
  • Received prior cetuximab or other EGFR-directed therapy, or history of prior anti-cancer murine or chimeric monoclonal antibody therapy; prior humanized and human monoclonal antibody therapy is also excluded.
  • Received prior treatment with bevacizumab or other agents specifically targeting VEGF or VEGF receptors
  • Uncontrolled intercurrent illness including, not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the Investigator/Treating Physician
  • Serious or non-healing active wound ulcer, or active bone fracture
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of protocol treatment
  • Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 1
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
  • Current or recent use of a thrombolytic agent within last 30 days. Use for clearance of central line catheter is permitted.
  • Evidence of bleeding diathesis (disorder) or clinically significant coagulopathy (Note that deep venous thrombosis is not regarded as a reason for exclusion from this trial)
  • Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • History of arterial thromboembolic events within 6 months
  • Urine protein:creatinine ratio greater than 1.0 at screening
  • Pregnant or lactating woman
  • Known to be HIV positive or receiving combination anti-retroviral therapy
  • Unable to comply with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252564


  Show 82 Study Locations
Sponsors and Collaborators
US Oncology Research
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Prologue Research International
Investigators
Layout table for investigator information
Principal Investigator: Allen Cohn, MD US Oncology Research
Principal Investigator: Leonard Saltz, M.D. Memorial Sloan Kettering Cancer Center

Layout table for additonal information
Responsible Party: US Oncology Research
ClinicalTrials.gov Identifier: NCT00252564     History of Changes
Other Study ID Numbers: 05-041
First Posted: November 11, 2005    Key Record Dates
Results First Posted: March 14, 2011
Last Update Posted: February 15, 2019
Last Verified: September 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Cetuximab
Oxaliplatin
Fluorouracil
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors